Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia

Cancer

Volumn 94, Issue 7, 2002, Pages 2024-2032

  O'Brien, Susan ^a   Talpaz, Moshe ^a   Cortes, Jorge ^a,c   Shan, Jianqin ^a   Giles, Francis J ^a   Faderl, Stefan ^a   Thomas, Deborah ^a   Garcia Manero, Guillermo ^a   Mallard, Susie ^a   BethRios, Mary ^a   Koller, Charles ^a   Kornblau, Steve ^a   Andreeff, Michael ^a   Murgo, Anthony ^a,b   Keating, Michael ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Leukemia and Lymphoma Society of America   (Canada)

Author keywords

Chronic myeloid myelogenous leukemia; Chronic phase; Homoharringtonine; Interferon

Indexed keywords

ALPHA INTERFERON; ERYTHROPOIETIN; HOMOHARRINGTONINE; IMATINIB;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMIA REMISSION; MALE; PAIN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HARRINGTONINES; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0036534203     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10436     Document Type: Article

References (25)

1. Treatment of chronic myelogenous leukemia: Current status and investigational options
2. Chronic myelogenous leukemia: Update on biology and treatment
3. Interferon-alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
4. Cytarabine increases karyotypic response in alpha-IFN treated chronic myeloid leukemia patients: Results of a national prospective randomized trial
5. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low dose cytosine arabinoside
6. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
7. UK Medical Research Council randomized, multicenter trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response
8. Interferon alpha versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
9. Cephalotaxine esters in the treatment of acute leukemia: A preliminary clinical assessment
10. On the treatment of leukemias: Clinical analysis of 72 cases
11. Homoharringtonine an effective new drug for remission induction in refractory nonlymphoblastic leukemia
12. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia
13. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
14. Phase II study of homoharringtonine in refractory acute myelogenous leukemia
15. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
16. Effect of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on "in vitro" growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors
17. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
18. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
19. Clinical course and therapy of chronic myelogenous leukemia with interferonalpha and chemotherapy
20. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy
21. Nonparametric estimation from incomplete observation
22. Regression models and life tables
23. Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival
24. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia